arGEN-X advances a third therapeutic antibody program into preclinical development: http://t.co/hBB8aUOQ
posted 17 hours ago
You have been successfully removed from this subscriber list. We will no longer send you information on this topic.
In case you want to unsubscribe from all FlandersBio e-mailings, please send an email to Jonas De Backer, Communications Coordinator at FlandersBio, with the subject 'Unsubscribe from all mailing lists'.
